Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ARDX vs NUVB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ARDX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)
ARDX Overall Winner
6-Pillar Tally: ARDX 5 – 1 NUVB
Matrix Metrics: ARDX 6 – 4 NUVB
As of Nov 20, 2026, Ardelyx, Inc. (ARDX) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ARDX carries a Unified Composite Score of 57.7/100 (HOLD) at $2.99 (18.9x Forward P/E, -7.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).
- Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ARDX 57.7/100 HOLD), ARDX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-7.7% vs. -61.2% operating margin) and revenue trajectory (+15.7% vs. +242.6% YoY).
- Technical & Structure Timing Caution: ARDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.3); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ARDX vs NUVB
ARDX
Head-to-Head Winner
Ardelyx, Inc.
$2.99
-2.29% 1D
Market Cap
$769.2M
TTM Revenue
$468M
Forward P/E
18.9x
Beta / 30D Vol
0.93β · 56% Vol
Unified Composite Score
57.7
HOLD
Tech 43.0
Fund 54.0
Flow 70.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
NUVB
Nuvation Bio Inc.
$3.80
-0.26% 1D
Market Cap
$1.3B
TTM Revenue
$202M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 55% Vol
Unified Composite Score
61.0
BUY
Tech 53.0
Fund 61.0
Flow 67.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ARDX 5 – 1 NUVB)
1. Valuation Multiples
ARDX
Forward P/E
18.9x
N/M
Trailing P/E
52.1x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
2.1x
7.4x
2. Growth & Scale
NUVB
Revenue Growth (YoY)
+15.7%
+242.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$468M
$202M
Market Cap
$769.2M
$1.3B
3. Profitability & Quality
ARDX
Gross Margin
74.3%
85.8%
Operating Margin
-7.7%
-61.2%
Net Profit Margin
-11.8%
-67.4%
Return on Equity (ROE)
-34.8%
-49.1%
4. Balance Sheet & Cash Flow
ARDX
Cash Generation (TTM)
-$16M
-$108M
Cash Flow Margin
-3.4%
-53.6%
Net Cash / Leverage
$210M Net Debt (1.56x D/E)
$146M Net Debt (1.32x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ARDX
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
52.1% (14th %ile)
65.2% (26th %ile)
Put/Call OI Skew
22.00x (Put-Skewed)
0.24x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
ARDX
OpEx & R&D Intensity
82.0% of Rev ($384M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ARDX (6) vs NUVB (4)| Institutional Metric | ARDX | NUVB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $769.2M | $1.3B | NUVB | |
| Trailing P/E Ratio | 52.1x | N/M | ARDX | |
| Forward P/E Ratio | 18.9x | N/M | ARDX | |
| Revenue Growth (YoY) | +15.7% | +242.6% | NUVB | |
| Operating Margin (TTM) | -7.7% | -61.2% | ARDX | |
| Net Profit Margin | -11.8% | -67.4% | ARDX | |
| Return on Equity (ROE) | -34.8% | -49.1% | ARDX | |
| 52-Week Range Position | 3% ($3–$8) | 2% ($4–$10) | ARDX | |
| Beta / 30D Volatility | 0.93β · 56% Vol | 1.52β · 55% Vol | NUVB | |
| Unified Institutional Score | 57.7 / 100 (HOLD) | 61.0 / 100 (BUY) | NUVB | |
| Trailing 12M Revenue (USD) | $468M | $202M | Scale | |
| Gross Profit Margin (TTM) | 74.3% | 85.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 2.1x EV/Rev | N/M PEG · 7.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$16M ($210M Net Debt (1.56x D/E)) | -$108M ($146M Net Debt (1.32x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ARDX +12.59 pp
3M Horizon
ARDX +23.74 pp
6M Horizon
NUVB +31.57 pp
1Y Horizon
ARDX +0.53 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ARDX Revenue | NUVB Revenue | ARDX Op. Margin | NUVB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -3488.6% | N/A | ARDX |
| FY2019 | $10M | N/A | -1728.1% | N/A | ARDX |
| FY2020 | $10M | N/A | -1199.0% | N/A | ARDX |
| FY2021 | $10M | N/A | -1528.6% | N/A | ARDX |
| FY2022 | $50M | N/A | -122.2% | N/A | ARDX |
| FY2023 | $120M | N/A | -50.8% | N/A | ARDX |
| FY2024 | $330M | $10M | -8.4% | -7527.3% | ARDX |
| FY2025 | $410M | $60M | -10.1% | -338.7% | ARDX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ARDX
BREAKDOWN
Current IV
52.1%
IV Percentile
14th %ile
Put/Call OI Skew
22.00x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact ARDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NUVB
BREAKDOWN
Current IV
65.2%
IV Percentile
26th %ile
Put/Call OI Skew
0.24x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ARDX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
82.0% of Rev ($384M)
90D Engineering Disclosures
0 Published
NUVB Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ARDX vs NUVB Key Questions & Quantitative Answers
As of Nov 20, 2026, Ardelyx, Inc. (ARDX) is the stronger overall head-to-head candidate over Nuvation Bio Inc. (NUVB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ARDX carries a Unified Composite Score of 57.7/100 (HOLD) at $2.99 (18.9x Forward P/E, -7.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. ARDX 57.7/100 HOLD), ARDX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-7.7% vs. -61.2% operating margin) and revenue trajectory (+15.7% vs. +242.6% YoY). Technical & Structure Timing Caution: ARDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.3); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NUVB leads the Growth & Scale pillar: ARDX posts +15.7% YoY revenue growth and +0.0% YoY earnings growth on $468M TTM revenue (74.3% gross margin, -7.7% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARDX cumulative revenue shifted +4000.0% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, ARDX deploys 82.0% of Rev ($384M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.
ARDX screens cheaper on headline valuation multiples. ARDX trades at 18.9x Forward P/E, 52.1x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-3.4% FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARDX (-34.8% ROE) versus NUVB (-49.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ARDX carries 52.1% implied volatility (14th %ile, Compressed (<25th %ile)), a 22.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.93β · 56% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NUVB vs ARDX · Reverse Pair
ARDX vs TGTX
· Sector Peer
NUVB vs LYEL
· Sector Peer
NUVB vs TSHA
· Sector Peer
NUVB vs STOK
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma